Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test

NCT04904510 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 297

Last updated 2023-02-15

Study results available
· View outcomes & findings →

Summary

The INDICAID™ Rapid Antigen Test was used in real-world outbreak testing. The antigen test was used together with PCR testing. This study was designed to evaluate whether the addition of a rapid antigen test decreased time to results in a real-world setting.

Conditions

  • Covid19

Interventions

DIAGNOSTIC_TEST

INDICAID™ COVID-19 Rapid Antigen Test

The diagnostic assay will be compared to a EUA SARS-CoV-2 assay

Sponsors & Collaborators

Eligibility

Min Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-11-20
Primary Completion
2021-03-09
Completion
2021-03-09
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04904510 on ClinicalTrials.gov